Investigational oral therapy for Friedreich's ataxia from PTC Therapeutics.

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.
Founded in 1998, PTC Therapeutics, Inc. is a US-based pharmaceutical company dedicated to developing orally administered, small-molecule drugs targeting genetic disorders, oncology, and infectious diseases. The company's core mission is to discover and commercialize innovative treatments that address unmet medical needs, improving the quality of life for patients worldwide. PTC Therapeutics focuses on creating therapies that are both effective and accessible, aiming to transform the landscape of rare disease treatment.
Notable figures affiliated with PTC Therapeutics include Stuart W. Peltz, a co-founder and key leader in the company's strategic direction. The company has attracted significant investment from prominent venture capital firms and institutional investors. Key achievements include the development and approval of several groundbreaking therapies, such as Translarna for Duchenne muscular dystrophy. PTC Therapeutics' impact is evident in its contributions to advancing medical science and providing hope to patients with rare and challenging conditions.
Companies similar to PTC Therapeutics include Adjuvia Therapeutics, Sarepta Therapeutics, Amicus Therapeutics and Amylyx Pharmaceuticals.
PTC Therapeutics was founded in 1998.
PTC Therapeutics' headquarters is located in South Plainfield, NJ, US.
PTC Therapeutics' most recent funding round was for $1B (USD) in October 2022.
As of Oct 27, 2022, PTC Therapeutics has raised a total of $1.6B (USD).
PTC Therapeutics has 1,402 employees as of Feb 6, 2024.

Amicus Therapeutics
amicusrx.com